Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma

Affiliations

• ¹ Division of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, Canada.
• ² Asthma & Airway Centre, University Health Network, Toronto, Canada.
• ³ Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.
• ⁴ Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
• ⁵ Fraunhofer Institute of Toxicology and Experimental Medicine and Respiratory Medicine of Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany.
• ⁶ Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.
• ⁷ Department of Microbiology Immunology and Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.
• ⁸ Department of Clinical Pharmacy and Pharmacology, UMCG and QPS Netherlands, Groningen, The Netherlands.
• ⁹ Novartis Pharma AG, 4002, Basel, Switzerland.
• ¹⁰ Novartis Institutes for BioMedical Research, Translational Medicine, Basel, Switzerland.
• ¹¹ Novartis Pharma AG, 4002, Basel, Switzerland. ivan.nikolaev@novartis.com.